雅視光學(01120.HK)年度淨虧5.1億港元 同比增加275.54%
格隆匯 3 月 29日丨雅視光學(01120.HK)公吿,截至2020年12月31日止年度,收入7.4億港元,同比減少28.66%;公司擁有人應占虧損5.1億港元,同比增加275.54%;每股虧損132.51港仙;無派息。
相較於2019年,2020年呈報的虧損增加主要歸因下列非例行經營因素:(i)於截至2020年12月31日止年度集團錄得投資物業重估公平值虧損3140萬港元;(ii)集團於2020年綜合收入較2019年下跌29%造成規模不經濟,以致對集團的盈利能力產生負面影響;及(iii)於回顧年度集團因解僱國內閒置員工而產生1390萬港元的經濟賠償。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.